Frontier Biotechnologies Co. of Chongqing has received SFDA approval to begin a Phase I trial of HIV drug, Albuvirtide, a member of the viral entry inhibitor class of HIV/AIDS drugs. Albuvirtide targets gp-41, a viral protein that serves as a portal of entry by HIV into healthy (CD4+) T cells. The Phase I trial, which will be conducted in Beijing, will evaluate the tolerability, pharmacokinetics, and antiviral activity of Albuvirtide in HIV-infected patients. More details...